U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. Cellular & Gene Therapy Products
  4. YIMMUGO
  1. Cellular & Gene Therapy Products

STN: 125810
Proper Name: immune globulin intravenous, human-dira
Tradename: YIMMUGO
Manufacturer: Biotest AG
Indication:

  • For the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age or older.

Product Information

  • Package Insert - YIMMUGO
  • Demographic Subgroup Information - YIMMUGO
    Refer to Section 1.1 of the Clinical Review Memo for information about participation in the clinical trials and any analysis of demographic subgroup outcomes that is notable.

Supporting Documents

 

Back to Top